NRXP - long - catalyst play
Zaktualizowano
NRX Pharmaceuticals Inc is a clinical-stage, small molecule pharmaceutical company which develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. It is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behaviour.
This is not a financial advice!
Upcoming catalysts 03/31/2024 and 06/30/2024
Today Rel. Vol. of 12.66
We need to stay in a bullish overal sentiment of the market. If we see a corretion, this play might doesn't work.
Keep an eye on 1.0, 1.5 levels, needs to get broken for a further upmove. You can take partial profits at these levels if u want to lock in gains.
SL under 0.5
TPs approx. 2.20
Most info on the chart.
Trade carefully!
This is not a financial advice!
Upcoming catalysts 03/31/2024 and 06/30/2024
Today Rel. Vol. of 12.66
We need to stay in a bullish overal sentiment of the market. If we see a corretion, this play might doesn't work.
Keep an eye on 1.0, 1.5 levels, needs to get broken for a further upmove. You can take partial profits at these levels if u want to lock in gains.
SL under 0.5
TPs approx. 2.20
Most info on the chart.
Trade carefully!
Transakcja zakończona: osiągnięto poziom stop
Join Discord channel:
whop.com/marketplace/contingent-traders/
contingenttrader.com/
whop.com/marketplace/contingent-traders/
contingenttrader.com/
Wyłączenie odpowiedzialności
Informacje i publikacje przygotowane przez TradingView lub jego użytkowników, prezentowane na tej stronie, nie stanowią rekomendacji ani porad handlowych, inwestycyjnych i finansowych i nie powinny być w ten sposób traktowane ani wykorzystywane. Więcej informacji na ten temat znajdziesz w naszym Regulaminie.